LSA
GNMK

Leonteq Securities AG’s GenMark Diagnostics, Inc GNMK Stock Holding History

Leonteq Securities AG’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-10,000
Closed -$146K – 1147
2020
Q4 		$146K Buy
+10,000
New +$133K 0.01% 613

Other funds holding GNMK

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Leonteq Securities AG's GNMK Position: Q1 2021 in Review

Leonteq Securities AG sold out of GenMark Diagnostics, Inc (GNMK) in Q1 2021, closing a stake of 10,000 shares — an estimated $146K sold.

Leonteq Securities AG first reported a position in GNMK in Q4 2020 and held it in 1 quarter. The position peaked at $146K in Q4 2020. 164 funds tracked by Wall St. Rank hold GNMK as of Q1 2021.

  • Leonteq Securities AG reported no remaining GenMark Diagnostics, Inc position as of Q1 2021 after selling out during the quarter.
  • Leonteq Securities AG sold 10,000 GenMark Diagnostics, Inc shares in Q1 2021, an estimated $146K.
  • Leonteq Securities AG first reported a position in GenMark Diagnostics, Inc in Q4 2020 and held it in 1 quarter.
  • Leonteq Securities AG's GenMark Diagnostics, Inc position peaked at $146K in Q4 2020.
  • 164 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q1 2021.

Based on Leonteq Securities AG's 13F filing for Q1 2021, filed 26 Mar 2026.